New Phase 2 Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

jonzobot

Rank: President [?]

Points: 2527 [?]

Votes: 20 Score: 3.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

New Phase 2 Trial

posted on Jan 03, 2023 02:03PM

Well, not really new, but new since the last I checked the trial database.

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Sponsored by Memorial Sloan Kettering Cancer Center (Zenith is a collaborator)

25 pts, estimated completion 2 years. Does not appear to be a drug combination trial - and therefore I think this is the only ongoing trial to dose patients with Zen-3694 alone.

8 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply